Patents by Inventor Marie Lindholm

Marie Lindholm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9879265
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Publication number: 20160289677
    Abstract: The present invention relates to conjugates of antisense oligonucleotides (oligomers) that target the APOB gene at position 2265 to 2277.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 6, 2016
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Marie Lindholm, Mark Turner, Henrik Orum
  • Publication number: 20160138025
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: May 19, 2016
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Publication number: 20150291958
    Abstract: The present invention relates to conjugates of LNA antisense oligonucleotides (oligomers) that target ApoB.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 15, 2015
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum, Mark Turner, Marie Lindholm
  • Patent number: 8563528
    Abstract: The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: October 22, 2013
    Assignee: Santaris Pharma A/S
    Inventors: Ellen Marie Straarup, Niels Fisker Nielsen, Marie Lindholm, Joacim Elmèn
  • Publication number: 20120122954
    Abstract: The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: June 30, 2010
    Publication date: May 17, 2012
    Inventors: Ellen Marie Straarup, Niels Fisker Nielsen, Marie Lindholm, Joacim Elmèn
  • Publication number: 20120004276
    Abstract: The present invention relates to oligomer compounds (oligomers), which target mtGPAT1mRNA in a cell, leading to reduced expression of mtGPAT1. Reduction of mtGPAT1 expression is beneficial for the treatment of certain medical disorders, such as overweight, obesity, fatty liver, hepatosteatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steatohepatitis (NASH), insulin resistance, and non insulin dependent diabetes mellitus (NIDDM).
    Type: Application
    Filed: June 24, 2009
    Publication date: January 5, 2012
    Inventors: Marie Lindholm, Ellen Marie Straarup